In Vivo Assessment of Calcineurin Inhibitor Toxicity in Children

描述（由申请人提供）：慢性钙调磷酸酶抑制剂（CNIs）对肾脏有毒并引起血管内皮功能障碍。维持肾功能和避免长期血管并发症是一个主要的挑战，特别是在儿童CNIs患者中。早期发现是减少免疫抑制剂毒性损害的关键。一旦发现，免疫抑制剂毒性造成的损害可以通过修改/个体化免疫抑制药物方案来减少。然而，用于早期检测的诊断工具和指导这种免疫抑制药物方案个体化的监测工具目前都是不可用的，临床实践仍然依赖于相对较晚和不敏感的标志物，如血清肌酐和侵入性方法，如经皮肾活检。我们假设- CNIs对肾病综合征患儿及肾移植后肾细胞和血管内皮细胞代谢的负面影响通过血浆和尿液代谢物模式的变化反映出来，并且-血浆和尿液代谢物标志物比目前临床建立的血清肌酐等标志物具有更好的敏感性和特异性。我们将采用基于研究者实验室建立的代谢物和蛋白质分子标记的独特综合策略来评估CNI他克莫司对儿科患者的毒理学机制。该提案将基于两项临床试验：一项基于需要CNI治疗的肾病综合征儿童患者（Aim 1，“学习数据集”），另一项基于肾移植后接受基于CNI他克莫司免疫抑制药物方案的儿童患者（Aim 2，在更复杂的研究人群中进行“概念验证”资格研究）。其中，这些研究将回答以下问题：-儿童肾病综合征患者血浆和尿液代谢物和蛋白质模式的变化是否足够敏感，足以反映CNIs在首次给药后对近端小管和血管内皮细胞代谢和功能的负面影响？尿代谢物和蛋白质模式的改变是否反映了cni诱导的线粒体功能障碍？对CNI肾毒性和血管内皮功能障碍更敏感的儿童是否可以在接触第一周和血清肌酐发生任何明显变化之前确定？血浆和尿液代谢物和蛋白质模式的改变是否也能作为更为复杂的肾移植患儿的有效诊断工具？这些代谢物和蛋白质模式的变化是否足以特异性地区分免疫抑制剂毒性与免疫和炎症性肾损伤？-血浆和尿液代谢物和蛋白质模式变化是否更敏感，从而预测血清肌酐等不太敏感的标志物的增加？如果成功，我们的研究结果不仅将提供CNI在体内肾脏和血管毒性的机制见解，而且还将为候选标记物发展为临床诊断工具提供概念验证。利用这些标志物可以(A)预测免疫抑制药物方案的耐受性和免疫抑制治疗的个体化，(B)监测同种异体移植物功能和CNI毒性，(C)改善临床长期结果。

DESCRIPTION (provided by applicant): Chronic calcineurin inhibitors (CNIs) are toxic to the kidney and cause vascular endothelial dysfunction. Maintenance of kidney function and avoidance of long-term vascular complications are a major challenge especially in pediatric patients treated with CNIs. The key to reducing the damage caused by immunosuppressant toxicity is early detection. Once detected, the damage caused by immunosuppressant toxicity can be reduced by modification/ individualization of the immunosuppressive drug regimen. However, both the diagnostic tools for early detection and the monitoring tools to guide such an individualization of immunosuppressive drug regimens are currently unavailable and clinical practice still relies on relatively late and insensitive markers such as creatinine in serum and on invasive methods such as percutaneous kidney biopsies. We hypothesize that - the negative effects of CNIs on kidney cell and vascular endothelial cell metabolism in pediatric patients with nephrotic syndrome and after kidney transplantation are reflected by changes in plasma and urine metabolite patterns, and - plasma and urine metabolite markers have better sensitivity and specificity compared to markers currently established in the clinic such as creatinine in serum. We will use a unique comprehensive strategy based on metabolite and protein molecular markers established in the investigators' laboratories to assess the toxicodynamic mechanisms of the CNI tacrolimus in pediatric patients. This proposal will be based on two clinical trials: one based on pediatric patients with nephrotic syndrome that require treatment with CNIs (Aim 1, "learning data set") and the other based on pediatric patients after kidney transplantation who receive an immunosuppressive drug regimen based on the CNI tacrolimus (Aim 2, "proof-of-concept" qualification study in a more complex study population). Among others, these studies will answer the following questions: - Are plasma and urine metabolite and protein pattern changes in pediatric patients with nephrotic syndrome sensitive enough to reflect the negative effects of CNIs on the metabolism and function of the proximal tubule and vascular endothelial cells already after the first dose? - Do changes of urinary metabolite and protein patterns reflect CNI-induced mitochondrial dysfunction? - Can children who are more sensitive to CNI nephrotoxicity and vascular endothelial dysfunction already be identified within the first week of exposure and before any noticeable changes in serum creatinine occur? - Will plasma and urine metabolite and protein pattern changes also be a valid diagnostic tool in the more complex kidney transplant children? - Will these metabolite and protein pattern changes be sufficiently specific to distinguish immunosuppressant toxicity from immune and inflammatory kidney injury? - Will plasma and urine metabolite and protein pattern changes be more sensitive and thus predict the increase of less sensitive markers such as creatinine in serum? If successful, our results will not only provide mechanistic insights into CNI renal and vascular toxicity in vivo but will also provide proof-of-concept for the development of candidate markers into clinical diagnostic tools. Utilization of these markers may allow for (A) predicting tolerability of an immunosuppressive drug regimen and individualization of immunosuppressive therapy, (B) monitoring allograft function and CNI toxicity, and (C) improving clinical long-term outcomes.